Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Fort Lee, NJ, July 31, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided the final clinical data update from the Phase 1b study of NXP800 in recurrent, platinum resistant, ARID1a-mutated ovarian cancer and reported on the progress towards the initiation of the Phase 1b program for NXP900.

Read more at globenewswire.com